MDS Pharma Services Appoints General Manager for Late Stage Development
06 Febbraio 2004 - 5:00PM
PR Newswire (US)
MDS Pharma Services Appoints General Manager for Late Stage
Development Dr. Grigore Voinov Will Have Responsibility for Central
and Eastern Europe And Asia Pacific MONTREAL, Feb. 6
/PRNewswire-FirstCall/ -- MDS Pharma Services, a leading provider
ofinnovative drug discovery and development solutions, has named
Dr. Grigore Voinov general manager -- Central and Eastern Europe
and Asia Pacific, announced Alan Morgan, vice president, Europe,
Late Stage Development. While continuing to focus on growth in
Eastern Europe, Voinov will develop MDS Pharma Services' global
clinical development business in Asia. Currently, the company
operates two late stage development facilities in this region. Its
Singapore location offers central lab services and recently added
global clinical development services, which should be fully
established by end of year. Its state-of-the-art facility in
Beijing is the first CAP-accredited lab in China and currently
provides clinical support and testing for the People's Republic of
China. "Dr. Voinov has experience and expertise in both
establishing offices in new geographical territories and working
collaboratively with partners to ensure the delivery of high
quality services to our clients. This position is a great fit,"
said Morgan. He brings nearly 20 years of experience into this
position, having served as general manager of Central and Eastern
Europe (CEE) for MDS Pharma Services and CEE operations director
for Phoenix International France (now part of MDS Pharma Services).
He holds a Doctorate in Medicine from the University of Medicine
and Pharmacy in Bucharest, Rumania. MDS Pharma Services offers a
full spectrum of resources to meet the drug discovery and
development needs of the pharmaceutical and biotechnology
industries. With numerous facilities strategically located around
the world, the company applies advanced scientific and
technological expertise to each stage of the drug discovery and
development process -- early stage: lead optimization, pre-IND
research, pharmaceutical and biopharmaceutical development, early
clinical research (bioequivalence, phases I-IIa) and bioanalysis;
and late stage: global clinical development (phases IIb-IV) and
central lab. For more information, visit MDS Pharma Services' Web
site at http://www.mdsps.com/ . MDS Pharma Services is part of MDS
Inc. (NYSE:MDZ)(TSE:MDS), an international health and life sciences
company. At MDS Inc., our 10,000 highly skilled people provide
services, products and instrumentsenabling health sciences
organizations to enhance the well being of people around the world.
We focus on helping discover and test new drugs, assisting doctors
to diagnose and treat patients and preventing the spread of
disease. Find out more about MDS Inc. (NYSE:MDZ)(TSE:MDS), at
http://www.mdsintl.com/ or by calling 1-888-MDS-7222, 24 hours a
day. DATASOURCE: MDS Pharma Services CONTACT: Kevin Langin of MDS
Pharma Services, +1-402-476-2811 Web site: http://www.mdsintl.com/
http://www.mdsps.com/
Copyright
Grafico Azioni Mds (NYSE:MDZ)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Mds (NYSE:MDZ)
Storico
Da Lug 2023 a Lug 2024
Notizie in Tempo Reale relative a Mds (Borsa di New York (NYSE)): 0 articoli recenti
Più Mds Articoli Notizie